186818-88-2Relevant academic research and scientific papers
Novel 1,2-diarylcyclobutenes: Selective and orally active COX-2 inhibitors
Friesen, Richard W.,Dube, Daniel,Fortin, Rejean,Frenette, Richard,Prescott, Sylvie,Cromlish, Wanda,Greig, Gillian M.,Kargman, Stacia,Wong, Elizabeth,Chan, Chi Chung,Gordon, Robert,Xu, Li Jing,Riendeau, Denis
, p. 2677 - 2682 (1996)
A series of novel 2,3-diaryl-2-cyclobuten-1-ones have been synthesized and have been evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1 and COX-2. 4,4-Dimethyl-2-phenyl-3-[4-(methylsulfonyl)phenyl]cyclobutenone 22 was found to be highly selective for inhibition of COX-2 and was orally active (ED50 = 2.4 mg/kg) in the rat paw edema model.
BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS
-
, (2008/06/13)
The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).
Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
-
, (2008/06/13)
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising
